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RXNormObjective: Create an automated algorithm for predicting elderly patients’ medication-related risks for
readmission and validate it by comparing results with a manual analysis of the same patient population.
Materials and methods: Outcome and Assessment Information Set (OASIS) and medication data were
reused from a previous, manual study of 911 patients from 15 Medicare-certiﬁed home health care agen-
cies. The medication data was converted into standardized drug codes using APIs managed by the
National Library of Medicine (NLM), and then integrated in an automated algorithm that calculates
patients’ high risk medication regime scores (HRMRs). A comparison of the results between algorithm
and manual process was conducted to determine how frequently the HRMR scores were derived which
are predictive of readmission.
Results: HRMR scores are composed of polypharmacy (number of drugs), Potentially Inappropriate Med-
ications (PIM) (drugs risky to the elderly), and Medication Regimen Complexity Index (MRCI) (complex
dose forms, instructions or administration). The algorithm produced polypharmacy, PIM, and MRCI scores
that matched with 99%, 87% and 99% of the scores, respectively, from the manual analysis.
Discussion: Imperfect match rates resulted from discrepancies in how drugs were classiﬁed and coded by
the manual analysis vs. the automated algorithm. HRMR rules lack clarity, resulting in clinical judgments
for manual coding that were difﬁcult to replicate in the automated analysis.
Conclusion: The high comparison rates for the three measures suggest that an automated clinical tool
could use patients’ medication records to predict their risks of avoidable readmissions.
 2014 Elsevier Inc. All rights reserved.1. Introduction
1.1. Background
Avoidable hospital readmissions are indicators of ‘‘wasteful’’
health care spending [1] and of poor quality care and discharge
planning for patients. A 2003–2004 claims analysis found that a
ﬁfth of Medicare patients were rehospitalized within 30 days of
initial discharges, and that 90% of those readmissions were
unplanned [2]. The cost to Medicare in 2004 alone was $17.4
billion, the analysis found, and the readmissions were associated
with longer follow-up hospital stays. Estimates vary widely in
terms of how many unplanned readmissions are avoidable, [3]
but all hospital stays expose patients to risks of delirium, infections
and iatrogenic consequences of tests and procedures [4,5]. Identi-fying patients at greatest risk and offering them support to prevent
readmissions has consequently become a top priority for hospitals
– especially now that the federal Medicare program ﬁnancially
penalizes hospitals with 30-day readmission rates deemed unac-
ceptably high [6].
Some health systems and hospitals have reported early success
in identifying patients at risk for potentially avoidable readmis-
sions [7] and providing these at-risk patients with post-discharge
home visits and other preventive care services [8–10]. However,
one study concluded the evidence in favor of such post-discharge
programs remains weak [11] and another concluded that systems
to identify patients at greatest risk for readmissions have ‘‘per-
formed poorly’’ [12]. Meanwhile, two-thirds of U.S. hospitals are
paying federal penalties for having more readmissions than would
be expected given their patient populations [13].
In the search for a better way to reduce readmissions, focusing on
medications would seem to offer a promising target. A survey of 377
elderly patients discharged from Yale-New Haven Hospital found
81.4% of elderly patients experienced medication problems after
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drug regimens or because doctors erred inmaking prescriptions, set-
ting doses, or telling patients to stop taking drugs they needed [14].
Just the prescribing of medications with known risks that outweigh
beneﬁts for the elderly added an estimated $7 billion to U.S. health-
care expenditures in 2001 [15]. Recent research has evaluated
whether readmissions are associated with polypharmacy (patients
who take multiple medications) [16–18]; Potentially Inappropriate
Medication (PIM, drugs known to be risky to the elderly) [17]; or
medication regimen complexity (drugs with complex dose forms,
instructions and administration) [19,20].While research has demon-
strated an association between polypharmacy and avoidable read-
missions, at least one study failed to ﬁnd a relationship [21]. PIM
alone has not emerged as a meaningful indicator [17].
Dierich hypothesized that these variables did not consistently
predict readmission on their own, and used factor analysis to con-
struct a measure called high risk medication regimens (HRMRs)
that combined all three [22]. A structural equation model using
HRMR as a mediating variable was more predictive of readmissions
than using comorbidity or any of the three components on their
own as mediating variables. HRMRs accounted for a unique vari-
ance of 10% in patients’ readmission risks as well as 20% of the
comorbidity effect of readmission [22].
However, the manual process of deriving HRMR scores for this
study was tedious and limited the utility of this discovery. Auto-
mation of this process is necessary for follow-up research to verify
the predictive power of HRMRs, and for the potential development
of a clinical tool that uses prescription data from electronic health
records to assess patients’ readmission risks.
1.2. Objective
This study seeks to advance Dierich’s discovery by developing an
automated algorithm for determining HRMR scores – thereby
determining which patients are at greater risk for medication-
related hospital readmissions and would beneﬁt the most from
medication management services. The speciﬁc aims are to:
(1) map medication data automatically to RxNorm coding stan-
dards (2) create an automated algorithm that uses the coded med-
ication data to calculate patient HRMR scores for easy replication
and application across different health care systems and databases,
and (3) test the algorithm’s accuracy by seeing if it derived the same
HRMR scores that Dierich calculated through her manual analysis.
2. Materials and methods
2.1. Data set
The data set developed in Dierich’s study was utilized for this
study. It contains Outcome and Assessment Information SetTable 1
RXCUI examples with corresponding TTY types.
TTY TTY name TTY description [15]
IN Ingredient A compound or moiety that gives the drug its distinctive c
BN Brand name A proprietary name for a family of products containing a s
MIN Multiple
ingredients
Two or more ingredients appearing together in a single dr
rare cases when IN/PIN or PIN/PIN combinations of the sam
SCD
DF Dose form Dose form
SCDF Semantic
clinical drug
form
Ingredient + Dose Form
SCD Semantic
clinical drug
Ingredient + Strength + Dose Form
SBD Semantic
branded drug
Ingredient + Strength + Dose Form + Brand Name(OASIS) and medication data from 911 older adults from 15
Medicare-certiﬁed home health care agencies. Patients were 65
and older whose ﬁrst episodes of home care took place after initial
hospitalizations in 2004. Home care clinicians reviewed the medi-
cation records and validated their accuracy by observing the med-
ications in patients’ homes. Only patients with complete OASIS and
medication records were included in the data set. OASIS is a com-
prehensive assessment tool completed by home care clinicians to
track conditions of patients at admission, various points during
their episodes of care, and discharge [22]. It is used to calculate
outcome and risk factors of patients in Medicare-certiﬁed home
care agencies, and includes demographic, environmental, support
system, health and functional status, and health service utilization
information [23]. The medication data includes all prescribed and
over-the-counter medications and contained the medication name,
dose, frequency, dose forms, frequencies and special instructions.
2.2. Coding standard deﬁnitions
RxNorm: A standardized nomenclature for clinical drugs that is
produced by the National Library of Medicine (NLM) [24].
RxNorm’s standardized naming conventions allow health systems,
which might catalog drugs in different ways in their computer sys-
tems, to communicate efﬁciently and accurately [25].
RXCUI: A unique numerical identiﬁer for clinical drugs and their
concepts. Medications with the same RXCUIs are considered the
same drugs with the same ingredients, strengths and dose forms.
TTY: Term types (TTYs) are used along with RXCUIs to further
identify generic and branded drug by their properties (ingredients,
dose forms, etc.) Examples are shown in Table 1.2.3. Tools used in conjunction with coding standards
RXNORM APIs: Online tools that convert drug descriptions
from datasets into normalized RxNorm drug codes for research
and analysis [26]. Examples from this study are in Table 2.
2.4. Methods
2.4.1. HHC medication record data converted to coding standards
In Dierich’s study, medication record data was cleansed as
follows:
 Medication names were converted to generic names.
 A patient’s ‘‘likely disease’’ was derived from the medication’s
indication. (While the OASIS records contained ICD9 diagnostic
values for a patient, the records were limited to one primary
and ﬁve secondary diagnoses. In addition, medications were
not linked to ICD9 codes, and could have been used for reasons
for which there are no diagnostic codes.)RXCUI RXCUI string
linical properties 2541 Cimetidine
peciﬁc active ingredient 152402 Tagamet
ug preparation, created from SCDF. In
e base ingredient exist, created from
818150 Alginic acid/Cimetidine
316949 Injectable solution
371513 Cimetidine injectable
solution
309296 Cimetidine 1.8 MG/ML
injectable solution
205746 Cimetidine 6 MG/ML
injectable solution [Tagamet]
Table 2
Example mapping local medications to RXCUI values.
API name Description [17] Example API calls Example record(s) returned
ApproxMatch(term) Search by name to ﬁnd the
closest RxNorm concepts
ApproxMatch(Cimetidine) RXCUI: 2541SCORE: 100RANK: 1RXCUI: 91215SCORE: 100RANK: 1
GetRXConceptProperties(rxcui) Return the concept’s
properties
getRXConceptProperties
(2541)
STR:CimetidineTTY: INRXCUI: 2541
GetAllRelatedInfo(rxcui) Get all the related RxNorm
concepts for a given
RxNorm identiﬁer
GetAllRelatedInfo(2541) STR: TagametTTY: BNRXCUI: 152402STR: alginic acid/CimetidinTTY:
MINRXCUI: 818150STR: Cimetidine 6 MG/ML Injectable Solution
[Tagamet]TTY: SBDRXCUI: 205746STR: Cimetidine 1.8 MG/ML
Injectable SolutionTTY: SCDRXCUI: 309296
getAllConceptsByTTY(termtypes) Return the RxNorm
concepts for the speciﬁed
term types
getAllConceptsByTTY(DF) STR: Injectable SolutionTTY: DFRXCUI: 316949STR: Inhalant
PowderTTY: DFRXCUI: 317000STR: Ophthalmic SolutionTTY: DFRXCUI:
7670
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were manually derived by splitting the medication text into
appropriate concepts.
To further prepare the data for this study, medication names
were converted to RXCUI values with a TTY of IN or MIN. A SAS
program was created that used RXNORM APIs for this conversion
(Fig. 1). Dierich’s medication dose forms were converted to RXCUI
values with a TTY of DF using a RXNORM API. Dose forms that were
not found by the API were converted to custom codes (Fig. 2). In
addition, a separate SAS program was created for future use to con-
vert Medication RXCUI values with a TTY of SCD, SCDF, or SBD to
Dose Form RXCUI values with a TTY of DF (Fig. 3).
‘‘Likely diseases’’ were manually converted to ICD9 values for
each patient based on the expertise of the authors – a doctorally
prepared informatician (Olson), a geriatric nurse practitioner (Die-
rich), and a nurse researcher with expertise in geriatrics and home
health care data (Westra), and validated against the Charlson
comorbidity index [27]. A separate record was created for each
patient consisting solely of ‘‘likely diseases’’ and corresponding
ICD9 values.Fig. 1. Medication nam
Fig. 2. Dose forms tLastly, medication frequencies and special directions were con-
verted to custom codes from Dierich’s manually derived values
from her previous study. No standard was found for these values
in the literature.
2.4.2. Polypharmacy automated algorithm
Dierich deﬁned polypharmacy as a continuous count of all reg-
ularly taken medications (prescribed or over the counter) via any
route listed in the ﬁrst episode of care [22]. Polypharmacy was also
used as a categorical variable for descriptive analysis; patients with
less than 9 medications were assigned a ‘‘0’’ and patients with 9 or
more medications were assigned a ‘‘1’’. PRN medications (those
used as needed), over-the-counter medications and medications
with limited dosing time such as antibiotics were included in the
count. The count excluded certain items documented in the
patients’ medication records such as oxygen or saline used to
dilute IV medications. Combination and variable dosed drugs were
counted as one drug, rather than counting each active ingredient as
a separate drug.
An automated algorithm was created to count medication
records containing RXCUI values, and also count each medicationes to RXCUI values.
o RXCUI values.
Fig. 3. Dose forms to RXCUI values – future use.
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logic and cleansed data as Dierich used in her study.2.4.3. Potentially inappropriate medications automated algorithm
The 2003 version of the Beers’ criteria, a list of 48 drugs and 20
drug classes that the elderly should avoid, was used in Dierich’s
study to create PIM scores [28]. There is a newer version of the
Beers criteria, but it was not available at the time of Dierich’s study,
hence the same version was used in this study for comparison of
the manual process and algorithm. In the Beers’ criteria, Fick
et al. identiﬁed two categories of inappropriate drugs: PIM Table 1
includes those inappropriate for older adults no matter their diag-
nosis and PIM Table 2 includes medications that could be inappro-
priate depending on the diagnosis. The criteria also differentiated
drugs by whether or not they posed risks of severe adverse out-
comes (Appendix A).
Fick et al. did not assign scores to medications; hence, based on
clinical judgment, Dierich operationalized the PIM criteria by
assigning a score of 2.5 to each medication that was considered
always inappropriate, and a score of 2 for each medication with a
lower severity ranking. For medications with risks related to spe-
ciﬁc diseases, the assigned scores were 1.5 for medications with
the highest risks and 1.0 for medications with lower risks. A drug
may have more than one score, and the highest score was kept
for each drug. The medication scores were then summed to provide
a total risk level score for each patient.2.4.3.1. PIM Table 1 automated algorithm. A SAS program was cre-
ated to generate a crosswalk that maps drug names from PIM
Table 1 to RXCUI values with TTY types of IN, MIN, BN, SCD, SCDF
and SBD. The program used RXNORM APIs to generate the RXCUI
values. It also assigned Dierich’s score to each medication record
(Fig. 4). Another SAS program matched RXCUI crosswalk informa-
tion and patient medication records to produce PIM Table 1 scores
(Fig. 5).Fig. 4. PIM Table 1 c2.4.3.2. PIM Table 2 automated algorithm. A SAS program was cre-
ated to generate a crosswalk that maps medication names to
RXCUI values, and medication classes to medication names to
RXCUI values. The NLM Drug portal was used to map medication
classes to medication names. A standard was not used for the drug
class, and the medication class from PIM Table 2 was manually
typed into the web portal which then displayed all medications
for that drug class. A SAS program then converted the medication
names to RXCUI values using RXNORM APIs. Clinical judgment
was used to manually map diagnoses to ICD9 values. The ICD9 val-
ues were then assigned to each entry of the crosswalk along with
Dierich’s score (Fig. 6). Another SAS program combined medication
records, patients’ likely diseases, and PIM Table 2 crosswalk data to
produce patients’ PIM Table 2 scores (Fig. 7).
2.4.4. Medication regimen complexity automated algorithm
Dierich used a modiﬁed version of the Medication Regimen
Complexity Index (MRCI) developed by George et al., because at
the time it was ‘‘the only validated and reliable non-disease spe-
ciﬁc measure addressing medication complexity in the published
literature’’ [29]. The index utilizes weighted scores in three sub-
scales – by the complexity of their route (MRCI Table A), their dos-
ing frequency (MRCI Table B), and their directions or preparation
(MRCI Table C) – and then combines the subscale scores into a
summary score (Appendix B). George et al. did not provide a cut
point for highly complex regimens. Dierich used a continuous score
in her structural equation modeling, and a cut point of 20 or above
in her categorical data analysis as an indication of high medication
regimen complexity.
2.4.4.1. MRCI Table ‘‘A’’ automated algorithm. A SAS program was
created to generate a crosswalk that maps the dose forms fromMRCI
Table A to RXCUI values with a TTY type of DF using a RXNORM API.
Dose forms that were not found with the API were converted to cus-
tom codes (Fig. 8). Similar to its use in PIM scoring, a SAS program
generated patients’ MRCI Table A scores through the input of medi-
cation records and MRCI Table A crosswalk data (Fig. 9).rosswalk design.
Fig. 5. PIM Table 1 automate patient score.
Fig. 6. PIM Table 2 crosswalk design.
64 C.H. Olson et al. / Journal of Biomedical Informatics 51 (2014) 60–712.4.4.2. MRCI Table ‘‘B’’ and ‘‘C’’ automated algorithm. SAS programs
were created to generate a crosswalk that maps custom codes for
dosing frequency and special directions to MRCI Table B and C.
Two other SAS programs were created to then generate patients’
MRCI Table B and C scores. The programs entered the medication
records, and then MRCI Table B and Table C crosswalks, and pro-
duced the patients’ MRCI Table B (Fig. 10) and C scores (Fig. 11).3. Results
Results in this study include the percent of medications from
Dierich’s study that were automatically mapped to RXCUI values
for both dose forms and medication names, as well as the poly-
pharmacy, PIM and MRCI patient scores that were produced
through this conversion of drug names.3.1. Mapping results
Overall, 99% of drugs in the medication data set were converted
to RXCUI values. Initially, without any manipulation of Dierich’s
data, 82% of the drug names were converted to RXCUI values.The 82% consisted of exact generic drug names that were recog-
nized by the API. After adjusting the data to redeﬁne combination
drugs with multiple ingredients into the naming formats that the
NLM API expected, the match rate increased to 90%. (Dierich used
‘‘And’’ instead of ‘‘/’’ in the names for multi-ingredient drugs. So
‘‘aspirin and dipyridamole’’ was reformatted to ‘‘aspirin / dipyrid-
amole’’.) Another 9% of the drug records were then converted,
either by using the brand names in Dierich’s data to ﬁnd the active
ingredient(s) RXCUI types of ‘‘IN’’ or ‘‘MIN,’’ or by correcting mis-
spellings in generic drug names. In the end, 1% of drug records
could not be converted; they lacked speciﬁc generic or brand
names. Rather, the medication terms represented broad medica-
tion categories such as ‘‘Laxative’’ or ‘‘Sports Cream’’.
Lastly, 80% of the dose forms in Dierich’s study were converted
to RXCUI values. Custom codes were created for irrigant, g-tube,
intravesicle, dressing, nebulizer and peg tube values. After adding
custom codes, 100% mapping of dose forms was achieved.
3.2. Polypharmacy results
Polypharmacy was calculated two ways: by counting
medication records containing RXCUI values, and by counting each
Fig. 7. PIM Table 2 automate patient score.
Fig. 8. MRCI Table A crosswalk design.
Fig. 9. MRCI Table A automate patient score.
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The count of all medication records for patients produced a 100%
match to Dierich’s data. The count of records with RXCUI values
per patient produced a 99% match to Dierich’s data.
3.3. PIM table results
The match between the automation of patients’ PIM scores and
Dierich’s manual PIM counts was 87%. PIM Table 1 consists ofpotentially inappropriate medications independent of patients’
diagnoses. PIM Table 2 consists of potentially inappropriate medi-
cations that were linked to diagnoses. Medications could have
more than one score between PIM Table 1 and PIM Table 2; the
highest score was assigned to the medication.
In order to reach 87%, the manual calculations and logic in the
automated design were adjusted (Table 3). The manual count, for
example, included all long acting NSAIDs, such as diclofenac,
whereas the automated count only included speciﬁc drugs in PIM
Fig. 10. MRCI Table B automate patient score.
Fig. 11. MRCI Table C automate patient score.
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the PIM Table 1 crosswalk to be included in patients’ scores and to
increase the match rate. The automation for PIM Table 2 found
more drugs in diagnosis-speciﬁc drug classes than the manual
scoring. More muscle relaxants such as quinine, for example, were
found by the automated search of patients’ medication records.
These drugs were removed from the PIM Table 2 crosswalk so they
would not be included in the patients’ automated scores. The auto-
mation also caught mistakes made in the manual review, such as
not applying medications consistently across all patients’ records.
The correction of these errors resulted in modest changes to the
manually derived PIM scores.
The 13% that did not match included drugs that were obscured
by the conversion of all drug names to their generic forms and to
RXCUI values. For example, there is only one RXCUI value for theTable 3
Adjustments to automated and manual logic.
Discrepancy with manual approach Resoluti
Automation only included dose amount for drugs which included amount
guidelines such as ferrous sulfate > 325 mg/d
Automa
Automation only considered speciﬁc drugs in PIM Table 1, even when a
drug class was identiﬁed in combination with speciﬁc drugs
Automa
gastroin
Automation did not identify tegaserod and scopolamine as anticholinergic Tegasero
Automation did not identify all benzodiazepines Lorazepa
and 2 cr
Automation did not identify all stimulant laxatives Senna a
Automation did not exclude coxibs from NSAID drug Class Rofecox
Automated approach included quinine as a muscle relaxant Quininegeneric nifedipine. The manual calculations used the brand names
and differentiated between long- and short-acting formulations of
this medication. The automated design did not, because it utilized
the single RXCUI value from the generic conversion. The drugs that
did not match also included those with dose or form consider-
ations such as Estrogen which were considered in the manual cal-
culations but not the automated design. Future adjustments to the
automated design could allow it to account for these consider-
ations (Table 4).
3.4. MRCI Table A results
MRCI Table A consisted of complex dose forms and a corre-
sponding weighting assigned to each entry of the table. The follow-
ing results were produced for MRCI Table A:on
tion adjusted to include dose and frequency
tion adjusted to consider all drugs for muscle relaxants and antispasmodics,
testinal antispasmodic drugs, anticholinergics and antihistamines
d and scopolamine added to PIM Table 2 crosswalk
m, oxazepam, temazepam, alprazolam, and clonazepam added to PIM Tables 1
osswalks
nd magnesium hydroxide added to PIM Table 1 crosswalk
ib and celecoxib removed from PIM Table 2 crosswalk
removed from PIM Table 2 crosswalk
Table 4
Future adjustments.
Drug/drug class Issue Future resolution
Short acting nifedipine (Procardia and Adalat) Identifying short vs.
long acting nifedipine
The automated algorithm used the generic RXCUI value of 7531 (TTY = IN), because the
medication data was stored with generic RXCUI values.Only RXCUI values related to short
acting Nifedipine should be included in the PIM Table 1 crosswalk. The crosswalk may then
be used with medication data stored with RXCUI formats which include the short acting
speciﬁcation. Examples below:491072 (TTY = SBDF): Nifedipine Extended Release Tablet
[Adalat]198034 (TTY = SCD): 24 HR Nifedipine 30 MG Extended Release Tablet672918
(TTY = SBD): 24 HR Nifedipine 90 MG Extended Release Tablet [Adalat]
Muscle relaxants and antispasmodics: Do not
consider theextended-release Ditropan XL
Identifying extended
release Ditropan XL
The automated algorithm used the generic RXCUI value of 32675 (TTY = IN) for oxybutynin.
Exclusion criteria may be identiﬁed with RXCUI values stored in a format which includes
the extended release speciﬁcation. Examples below:863622 (TTY = SBD): 24 HR Oxybutynin
chloride 10 MG Extended Release Tablet [Ditropan] 863621 (TTY = SBDF): Oxybutynin
Extended Release Tablet [Ditropan]863619 (TTY = SCD): 24 HR Oxybutynin chloride 10 MG
Extended Release Tablet
Estrogen (Oral) Identifying oral dose
form
The automated algorithm used the generic RXCUI value of 4099 (TTY = IN) for estrogen
Only RXCUI values for Oral Estrogen should be deﬁned in the PIM Table 1 crosswalk. The
crosswalk may then be used with medication data stored with RXCUI formats which include
the oral dose form speciﬁcation. Examples below:1441737 (TTY = SBDF): bazedoxifene /
Estrogens, Conjugated (USP) Oral Tablet [Duavee]197662 (TTY = SCD): Estrogens,
Conjugated (USP) 1.25 MG Oral Tablet1441740(TTY = SBD): bazedoxifene 20 MG /
Estrogens, Conjugated (USP) 0.45 MG Oral Tablet [Duavee]
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MRCI Table A dose forms to RXCUI dose form values, the match
was 80% to Dierich’s manual calculations.
 When the automation ran against a crosswalk that converted
MRCI Table A dose forms to RXCUI dose form values, and
included custom values for irrigant, g-tube, intravesicle, dress-
ing, nebulizer and peg tube, the match was 99% to Dierich’s
manual calculations.
3.5. MRCI Table B & MRCI Table C results
MRCI Table B consisted of complex dose frequencies and a cor-
responding weighting assigned to each entry of the table. MRCI
Table C consisted of complex special instructions and a corre-
sponding weighting assigned to each entry of the table. The auto-
mation of patients’ MRCI Table B and MRCI Table C scores produced
a 99% match.4. Discussion
Automated analysis of clinical data is rapidly emerging as a way
for health care providers to predict patient needs and risks for a
variety of disorders and adverse events [30,31]. McDonald et al.
in 2012 created a successful approach to determining MCRI scores
of patients in post-acute home care settings through an algorithm
using medication data from their electronic health records [32].
Medication data presents unique challenges in this pursuit, though,
because of the heterogeneous nature of prescription recordkeeping
by different health care providers and the lack of standards for
drug data coding and entry [33]. RxNorm is viewed as an ‘‘ideal
standard’’ for standardizing prescription data [34], and making it
available across health care systems for secondary analysis [35].
This study provides further validation of the utility of RxNorm
and of automated algorithms for secondary analysis, and takes an
important next step in applying this approach to the scoring of
HRMRs, which Dierich showed have unique potential to assess
medication-related risks for hospital readmissions. Automating
HRMR calculations was a step that Dierich found necessary for fur-
ther study in this area in order to ‘‘greatly improve the quality
of research, the accuracy of ﬁndings, and the speed of release of
ﬁndings’’ [22].4.1. Limitations
The absence of coding standards from the data used in the ori-
ginal Dierich study created several limitations in terms of the abil-
ity to truly automate the process of assembling HRMR scores and
analyzing patient readmission risks. If a medication record had a
misspelling for a dose or medication name, an RXCUI value was
not automatically found for that record, and manual editing was
needed to clean up the database.
For PIM Table 2, the NLM drug portal was used to ﬁnd all the
medication names associated with a medication class. This was
not a truly automated process, and drug class coding standards
were not used. Medication classes were typed into the portal to
ﬁnd associated medication names, and a SAS program was created
to map the medication names to RXCUI values using RxNorm APIs.
In addition, ICD9 values were manually mapped to a patient’s
likely disease. This study would have beneﬁted from automation
and tools to convert diagnosis text to ICD9 codes, just as this study
utilized NLM APIs to convert medication names to RXCUI values.
For MRCI Table A, the SAS program created to generate dose
form RXCUI values, based on medication RXCUI values, was created
for future use and was not validated with Dierich’s data. The data
did not consist of medication records that were stored by Semantic
Clinical Drug (SCD), Semantic Clinical Drug Dose Form Group
(SCDG) or Semantic Clinical Drug Form (SCDF). For MRCI Tables B
and C, informatics standards were not used, and custom codes
were created for dose frequency and special instructions.
The rapid expansion of electronic health records with common
or relatable terminologies – increased by federal meaningful use
ﬁnancial incentives for hospitals and clinics [36] – would address
some of the limitations experienced in this study. The standardiza-
tion of prescription information is necessary so that physicians can
review the safety of drug regimens with patients who transition
out of hospitals or to new levels of care. A secondary beneﬁt
beyond this process of medication reconciliation is more consis-
tency in the format of prescription information for data prepara-
tion and analysis. Federally funded projects such as SHARPn also
are developing open source tools that extract clinical text from dis-
parate EHRs and ‘‘normalize’’ it for secondary analysis [35]. An
attempt at using the HRMR algorithm in this study with a dataset
prepared under today’s EHR conditions and requirements would
likely result in fewer setup problems.
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The tool developed in this study is a novel approach for assess-
ing medication-related readmission risks that can be replicated
and applied across hospital and health care recordkeeping systems.
The APIs available through the NLM website, and the crosswalks
generated, allow the algorithm to be adapted and adjusted in other
systems for future clinical analysis and research. An important
next step is to adjust criteria in the automated algorithm to deter-
mine optimal cut-points that separate patients at higher risk of
hospitalization from patients who have lower risk based on their
high risk medication regime scores. The scores of 2.5, 2, 1.5 and
1 that Dierich used for PIM calculations were arbitrary based
on clinical judgment. Future users could determine that greaterTable A1
Potentially inappropriate medications: independent of diagnoses or conditions, from Fick
Drug/drug combinations with the active ingredient
Propoxyphene (Darvon)
Indomethacin (Indocin)
Pentazocine (Talwin)
Muscle relaxants and antispasmodics: methocarbamol (Robaxin), carisoprodol (Soma
cyclobenzaprine (Flexeril), and oxybutynin (Ditropan). Do not consider the extend
Flurazepam (Dalmane)
Amitriptyline (Elavil), chlordiazepoxide-amitriptyline (Limbitrol), and perphenazine-a
Doxepin (Sinequan)
Meprobamate (Miltown and Equanil)
Doses of short-acting benzodiazepines: doses greater than lorazepam (Ativan), 3 mg;
temazepam (Restoril), 15 mg; and triazolam (Halcion), 0.25 mg
Long-acting benzodiazepines: chlordiazepoxide (Librium), chlordiazepoxide-amitript
diazepam (Valium), quazepam (Doral), halazepam (Paxipam), and chlorazepate (T
Disopyramide (Norpace and Norpace CR)
Digoxin (Lanoxin) (should not exceed _0.125 mg/d except when treating atrial arrhyt
Short-acting dipyridamole (Persantine). Do not consider the long-acting dipyridamole
adults) except with patients with artiﬁcial heart valves
Methyldopa (Aldomet) and methyldopa-hydrochlorothiazide (Aldoril)
Reserpine at doses > 0.25 mg
Chlorpropamide (Diabinese)
Gastrointestinal antispasmodic drugs: dicyclomine (Bentyl), hyoscyamine (Levsin and
alkaloids (Donnatal and others), and clidinium-chlordiazepoxide (Librax)
Anticholinergics and antihistamines: chlorpheniramine (Chlor-Trimeton), diphenhydr
cyproheptadine (Periactin), promethazine (Phenergan), tripelennamine, dexchlorp
Diphenhydramine (Benadryl)
Ergot mesyloids (Hydergine) and cyclandelate (Cyclospasmol)
Ferrous sulfate > 325 mg/d
All barbiturates (except phenobarbital) except when used to control seizures
Meperidine (Demerol)
Ticlopidine (Ticlid)
Ketorolac (Toradol)
Amphetamines and anorexic agents
Long-term use of full-dosage, longer half-life, non–COX-selective NSAIDs: naproxen (
piroxicam (Feldene)
Daily ﬂuoxetine (Prozac)
Long-term use of stimulant laxatives: bisacodyl (Dulcolax), cascara sagrada, and Neo
Amiodarone (Cordarone)
Orphenadrine (Norﬂex)
Guanethidine (Ismelin)
Guanadrel (Hylorel)
Cyclandelate (Cyclospasmol)
Isoxsurpine (Vasodilan)
Nitrofurantoin (Macrodantin)
Doxazosin (Cardura)
Methyltestosterone (Android, Virilon, and Testrad)
Thioridazine (Mellaril)
Mesoridazine (Serentil)
Short acting nifedipine (Procardia and Adalat)
Clonidine (Catapres)
Mineral oil
Cimetidine (Tagamet)
Ethacrynic acid (Edecrin)
Desiccated thyroid
Amphetamines (excluding methylphenidate hydrochloride and anorexics)
Estrogens only (oral)scoring weight should be given to certain medications, such as
those presenting the greatest risks of severe adverse outcomes.
Using the algorithm to identify the most sensitive scores and cut-
pointswill hasten the use of HRMRas ameaningful source of patient
information in clinical, hospital and home health care systems.
Appendix A
Potentially inappropriate medications
(See Tables A1 and A2).
Appendix B
Medication regimen complexity indexet al. (2003, p. 2719), used with permission.
Low
risk
High
risk
X
X
X
), chlorzoxazone (Paraﬂex), metaxalone (Skelaxin),
ed-release Ditropan XL.
X
X
mitriptyline (Triavil) X
X
X
oxazepam (Serax), 60 mg; alprazolam (Xanax), 2 mg; X
yline (Limbitrol), clidinium-chlordiazepoxide (Librax),
ranxene)
X
X
hmias) X
(which has better properties than the short-acting in older X
X
X
X
Levsinex), propantheline (Pro-Banthine), belladonna X
amine (Benadryl), hydroxyzine (Vistaril and Atarax),
heniramine (Polaramine)
X
X
X
X
X
X
X
X
X
Naprosyn, Avaprox, and Aleve), oxaprozin (Daypro), and X
X
loid except in the presence of opiate analgesic use X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Table A2
Potentially inappropriate medication use: considering diagnoses or conditions, from Fick et al. (2003, p. 2721), used with permission.
Disease Drug Low
risk
High
risk
Heart failure Disopyramide (Norpace), and high sodium content drugs (sodium and sodium salts [alginate bicarbonate, biphosphate,
citrate, phosphate, salicylate, and sulfate])
X
Hypertension Phenylpropanolamine hydrochloride (removed from the market in 2001), pseudoephedrine; diet pills, and amphetamines X
Ulcers NSAIDs and aspirin (_325 mg) (coxibs excluded) X
Seizures or Epilepsy Clozapine (Clozaril), chlorpromazine (Thorazine), thioridazine (Mellaril), and thiothixene (Navane) X
Clotting Disorders,
Anticoagulation
Aspirin, NSAIDs, dipyridamole (Persantin), ticlopidine (Ticlid), and clopidogrel (Plavix) X
Bladder Outﬂow
Obstruction
Anticholinergics and antihistamines, gastrointestinal antispasmodics, muscle relaxants, oxybutynin (Ditropan), ﬂavoxate
(Urispas), anticholinergics, antidepressants, decongestants, and tolterodine (Detrol)
X
Stress Incontinence Alpha-Blockers (Doxazosin, Prazosin, and Terazosin), anticholinergics, tricyclic antidepressants (imipramine
hydrochloride, doxepin hydrochloride, and amitriptyline hydrochloride), and long-acting benzodiazepines
X
Arrhythmias Tricyclic antidepressants (imipramine hydrochloride, doxepin hydrochloride, and amitriptyline hydrochloride) X
Insomnia Decongestants, theophylline (Theodur), methylphenidate (Ritalin), MAOIs, and amphetamines X
Parkinson’s Disease Metoclopramide (Reglan), conventional antipsychotics, and tacrine (Cognex) X
Cognitive Impairment Barbiturates, anticholinergics, antispasmodics, and muscle relaxants. CNS stimulants: dextroAmphetamine (Adderall),
methylphenidate (Ritalin), methamphetamine (Desoxyn), and pemolin
X
Depression Long-term benzodiazepine use. Sympatholytic agents: methyldopa (Aldomet), reserpine, and guanethidine (Ismelin) X
Anorexia and
Malnutrition
CNS stimulants: DextroAmphetamine (Adderall), methylphenidate (Ritalin), methamphetamine (Desoxyn), pemolin, and
ﬂuoxetine (Prozac)
X
Syncope and Falls Short- to intermediate-acting benzodiazepine and tricyclic antidepressants (imipramine hydrochloride, doxepin
hydrochloride, and amitriptyline hydrochloride)
X
SIAHD; Hyponatremia SSRIs: ﬂuoxetine (Prozac), ﬂuvoxamine (Luvox), citalopram (Celexa), paroxetine (Paxil), and sertraline (Zoloft) X
Seizure Disorder Bupropion (Wellbutrin) X
Obesity Olanzapine (Zyprexa) X
COPD Long-acting benzodiazepines: chlordiazepoxide (Librium), chlordiazepoxide-amitriptyline (Limbitrol), clidinium-
chlordiazepoxide (Librax), diazepam (Valium), quazepam (Doral), halazepam (Paxipam), andchlorazepate (Tranxene);
beta-blockers: propranolol
X
Chronic Constipation Calcium channel blockers, anticholinergics, and tricyclic antidepressant (imipramine hydrochloride, doxepin
hydrochloride, and amitriptyline hydrochloride)
X
C.H. Olson et al. / Journal of Biomedical Informatics 51 (2014) 60–71 69The Medication Regimen Complexity Index, Section A (George
et al., 2004, p. 1374), used with permission.The Medication Regimen Complexity Index, Sections B and C
(George et al., 2004, p. 1375), used with permission.
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